Articles tagged with Cancer Treatments
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
The National Comprehensive Cancer Network (NCCN) has committed to updating its robust information resources for cancer patients and caregivers annually, available in both English and Spanish. The updated resources will provide factual, trustworthy information to guide patients and caregivers towards their best possible outcome.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
A new AI tool has been developed to predict the chances of death, major bleeding, or another cardiac event in cancer patients who have had a heart attack. The ONCO-ACS score combines cancer-related factors with standard clinical data to provide individualized treatment recommendations.
Researchers developed a new framework called SOLVE to overcome data challenges in precision cancer treatment. By jointly modeling known and unknown factors, SOLVE provides a robust tool for biomarker discovery and investigating tumor responses.
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
A large multinational clinical trial found that giving healthcare providers access to patient-reported outcome (PRO) data significantly improves the consistency of how treatment-related side effects are assessed in patients with cancer. This study highlights the importance of integrating the patient's voice into routine clinical evalua...
Research suggests that blocking growth factor receptor signaling using cancer drugs may overcome two challenges: managing oral cancer pain and preventing opioid tolerance. This approach could control cancer while addressing pain through a non-opioid, biologically rational approach.
A Mount Sinai study found that antibody-producing immune cells called IgG1 plasma cells help patients respond to PD-1 immune checkpoint inhibitors, which have transformed cancer care. The researchers identified IgG1 plasma cells as a critical factor in determining clinical outcomes.
Research reveals that chemotherapy alters the gut microbiota, producing indole-3-propionic acid, which travels to the bone marrow and rewires immune cell production. This leads to a metastasis-refractory state in preclinical models and improved survival outcomes in patients with colorectal cancer.
A study published by the National Institutes for Quantum Science and Technology found that carbon-ion radiotherapy provided durable tumor control with minimal side effects while preserving breast appearance in carefully selected patients who were unable or unwilling to undergo surgery. The treatment resulted in excellent local control ...
The report shows a notable increase in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers. Neoadjuvant systemic therapy increased notably for certain cancers, including gynecologic cancers, pancreatic cancer, and rarer abdominal lining cancers.
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
Researchers at UMass Amherst create a platform technology to target and destroy cancer-causing proteins, offering tailored treatments for specific cancers. A separate approach delivers fully functional proteins to reprogram cancerous cells, restoring their normal function.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
Large language models (LLMs) provide treatment recommendations for early-stage hepatocellular carcinoma (HCC) that align with clinical guidelines. However, their performance is limited in late-stage disease, where they prioritize tumor factors over liver function. LLMs should be used as a supplement to clinical expertise.
A machine learning model has identified the most important drivers of cancer survival in nearly all countries, highlighting factors such as national wealth, access to radiotherapy and universal health coverage. The model provides data-driven roadmaps for policymakers to prioritize resources and close survival gaps.
Researchers developed an algorithm using whole-genome sequencing to detect homologous recombination deficiency, a type of DNA-repair defect vulnerable to PARP inhibitors. The approach identified genetic mutations beyond BRCA1 and BRCA2, promising more accurate patient selection for cancer treatment.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
A Mass General Brigham study identifies new mutations that emerge in tumor cells following treatment, driving resistance in patients with different types of cancer. The researchers found two main categories of mutations: those impairing p53 function and others disrupting drug binding, highlighting a path forward for overcoming resistance.
Researchers at University of British Columbia have successfully grown specialized immune cells called helper T cells from stem cells in a controlled laboratory setting. This breakthrough could lead to more accessible and effective off-the-shelf treatments for various conditions, including cancer, autoimmune disorders, and infectious di...
The Mount Sinai Health System has launched an AI-powered clinical trial-matching platform, PRISM, to help connect patients with life-saving trials. The platform uses machine learning to match patients with trials based on their electronic health records and diagnosis.
The collaboration aims to integrate AI-powered analytics with clinical expertise to accelerate data-driven cancer care. MD Anderson researchers will leverage SOPHIAs AI technologies to develop bioinformatics pipelines for rapid RNA-sequencing data interpretation.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Two studies found that elevated bacteria levels in tumors weaken immune response, driving resistance to immunotherapy. Researchers are now exploring how to identify patients most likely to benefit from immunotherapy and develop targeted interventions to restore its effectiveness.
Researchers create a novel mathematical framework to control biological noise, enabling precise single-cell control. The 'Noise Robust Perfect Adaptation' technology suppresses stochastic fluctuations while maintaining stable average behavior, with promising applications in cancer therapy and synthetic biology.
A new study from Texas A&M University reveals that circadian disruptions change the structure of mammary glands, weaken immune defenses, and fuel aggressive breast cancer. Disabling an immune checkpoint molecule called LILRB4 helps restore the immune system's ability to fight back.
A new study by researchers from the Germans Trias i Pujol Research Institute provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer. The review highlights molecular, cellular, and tumour microenvironment factors that explain the therapeutic dichotomy between the two tumour types.
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers at UT Health San Antonio are developing APOBEC inhibitors to block tumor mutation rates and slow cancer's evolution. The goal is to strengthen current therapies and improve their long-term effectiveness.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at IIT identified a candidate molecule called Apt1 that enhances existing anticancer therapies by making tumour cells more vulnerable to chemotherapy drugs. The molecule slows DNA repair and impairs the interaction between RAD51 and BRCA2 proteins, inducing synthetic lethality in cancerous cells.
Researchers at EPFL have developed two bioengineering approaches that exploit extracellular vesicles to train dendritic cells to identify cancer cells without the need for tumor material. The approaches, published in Nature Communications and Science Translational Medicine, show promising results in enhancing cancer immunotherapy.
Researchers at Rockefeller University discovered that the T cell receptor springs open when activated by an antigen, contrary to previous studies. This finding could lead to next-generation treatments for a broader group of cancer patients.
Researchers at the University of Geneva have created a laboratory platform to rapidly evaluate the toxicity of new cancer treatments using human tissue-derived cell clusters. This approach allows for safer evaluation and could lead to personalized treatment options.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers at UT Health Sciences Center have developed an AI-enhanced platform called ENRICH, which leverages advanced analytics with community-based human support to reduce treatment interruptions and improve cancer outcomes. The program identifies patients at highest risk for interruption and deploys targeted support resources.
Maher El-Kady's work on sustainable energy storage technologies aims to create a cleaner, more accessible future. Dr. Dennis Slamon's breakthroughs in breast cancer treatment have benefited millions worldwide, highlighting the impact of UCLA researchers on global health and innovation.
Researchers have found that CAR T-cell therapy with cilta-cel leads to higher rates of complete remission and longer progression-free survival compared to ide-cel. Treatment success is linked to factors such as tumour burden, T-cell fitness, and systemic inflammation.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
Veterans and first responders face elevated risk of cancer due to occupational exposures, such as firefighting. Experts call for better access to high-quality cancer prevention, screening, and treatment, including presumptive laws and expanded support services.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
A study finds that most people trust doctors more than AI for health diagnoses, but have a positive view of AI's potential in cancer diagnosis. The research used two nationally representative surveys to assess public attitudes toward AI in healthcare, including trust, understanding, and excitement.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
A new study by Mayo Clinic researchers found that using digital check-ins and a remote care team can help patients manage symptoms before they reach a crisis point. The trial showed that the automated surveys and responses built into the electronic health record made care more efficient and improved patients' symptoms.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
A study published in JAMA Oncology found that shorter courses of androgen deprivation therapy can effectively control prostate cancer without increasing risks. The ideal duration of ADT depends on cancer risk, allowing for more personalized treatment plans.
Researchers developed a model using DNA methylation biomarkers and CT imaging to predict lymph node metastasis in early-stage gastric cancer patients. The tool helped reduce unnecessary invasive surgeries by up to 44%.
Researchers discover IRE1α pathway in immune cells triggers inflammation and nerve damage after chemotherapy, providing a potential target for prevention and treatment. Biomarkers may help identify patients at risk of developing chemotherapy-induced peripheral neuropathy.
A microRNA cocktail has been developed to weaken glioblastoma, a type of aggressive brain tumor. The formulation, comprising 11 different non-coding RNAs, slows the growth of cancer cells and enhances chemotherapeutic drug activity.
Lung cancer screening has the potential to prevent 3 times more deaths and gain 3 times more life-years than current levels. Increasing awareness and accessibility of lung cancer screening could lead to wider adoption.
Researchers at UC San Diego found that cancer cells use non-genetic mechanisms to regrow after targeted therapy, which could help prevent tumor recurrence. By blocking these signaling pathways, future treatments may be able to stop tumors from relapsing during therapy.
The new department will drive the next generation of discovery and patient-centered care through advanced imaging and therapy. Key collaborations include UCLA Health, David Geffen School of Medicine, and UCLA Health Jonsson Comprehensive Cancer Center.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for gastric cancer. The guidelines provide evidence-based recommendations for the role of radiation therapy in multidisciplinary care, including patient selection, integration with systemic therapy and treatment delivery.